Latest Comments

Insulin-related therapy: despite advances, unmet needs remain

Insulin-related therapy: despite advances, unmet needs remain

EULAR 2017: Lupus community remains divided on outcome measures

EULAR 2017: Lupus community remains divided on outcome measures

Tempered optimism for early IDO + PD1 dual checkpoint blockade data in advanced urothelial carcinoma

Tempered optimism for early IDO + PD1 dual checkpoint blockade data in advanced urothelial carcinoma

The Human Microbiome: On the cutting edge of future cures for many diseases?

The Human Microbiome: On the cutting edge of future cures for many diseases?

Beyond the indefinite treatment of chronic lymphocytic leukemia

Beyond the indefinite treatment of chronic lymphocytic leukemia

EMA withdrawal threatens UK patient access to cutting edge therapies

EMA withdrawal threatens UK patient access to cutting edge therapies

Improved and affordable diagnostics for kidney transplant rejection

Improved and affordable diagnostics for kidney transplant rejection

Unmet needs in melanoma treatment

Unmet needs in melanoma treatment

Verily aims to become a prophet of human health

Verily aims to become a prophet of human health

Quality-of-life improvements: DAA treatment from the patient’s perspective

Quality-of-life improvements: DAA treatment from the patient’s perspective

Where you live matters: geographic differences in DAA treatment access

Where you live matters: geographic differences in DAA treatment access

Trulance sNDA submission for IBS-C: a step forward for Synergy Pharmaceuticals

Trulance sNDA submission for IBS-C: a step forward for Synergy Pharmaceuticals

Rethinking future treatment options for sepsis: from immunosuppressive to immunostimulating drugs

Rethinking future treatment options for sepsis: from immunosuppressive to immunostimulating drugs

FOURIER outcomes data highlights the importance of value in drug development

FOURIER outcomes data highlights the importance of value in drug development

Unmet needs in the liver cancer market mean it’s full of potential

Unmet needs in the liver cancer market mean it’s full of potential

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

Amgen and Cytokinetics: approaching acute heart failure from a different angle

Amgen and Cytokinetics: approaching acute heart failure from a different angle

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data

Still hope for Lirilumab-Opdivo combination despite disappointing monotherapy data

When faster is not better: the 'surrogate' example

When faster is not better: the 'surrogate' example

Positive Phase IIb results position Synthetic Biologics’ Ribaxamase as serious contender for C. difficile Prophylaxis

Positive Phase IIb results position Synthetic Biologics’ Ribaxamase as serious contender for C. difficile Prophylaxis

ImmunoGen is poised to solve a major unmet medical need in ovarian cancer

ImmunoGen is poised to solve a major unmet medical need in ovarian cancer